Corvus Pharmaceuticals Welcomes New Board Member
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a pioneering clinical-stage biopharmaceutical company focused on innovating immunotherapies, is excited to announce the appointment of Richard A. van den Broek to its board of directors. This strategic move strengthens the leadership team with Mr. van den Broek’s extensive expertise in the biotechnology sector, which spans over three decades.
As managing partner at HSMR Advisors, Mr. van den Broek has demonstrated a robust track record as an investor and equity research analyst specializing in life sciences. His wealth of knowledge will bring valuable insights to Corvus as the company develops its innovative therapies.
Leadership's Take on the Appointment
“We’re thrilled to welcome Richard to our board,” expressed Richard A. Miller, M.D., the chairman, president, and CEO of Corvus Pharmaceuticals. “His proven experience in the biotechnology sector and deep understanding of the dynamics of the pharmaceutical market will be instrumental as we pursue our mission in advancing ITK inhibition and harnessing its potential to affect multiple signaling pathways within the immune system.”
Mr. van den Broek's Vision
In his acceptance of the role, Mr. van den Broek stated, “I am honored to join the Corvus board of directors at such a pivotal time for the company as it drives progress in its clinical pipeline. The ITK inhibition strategy is a significant opportunity that could transform treatment approaches for patients dealing with immune diseases and various cancers. My previous experience with Pharmacyclics, where we developed a similar therapy that led to the first BTK inhibitor approved for use, inspires my belief in Corvus’s vision.”
A Look at Mr. van den Broek's Career
Mr. van den Broek brings a wealth of experience to the Corvus team. Since 2004, he has held the position of managing partner at HSMR Advisors, LLC, guiding investment strategies within the biopharmaceutical sector. He has also served on the boards of Pulse Biosciences, Inc. and Cogstate Ltd, amplifying his influence and understanding of emerging therapies. His previous role on the board of Pharmacyclics, prior to its acquisition by AbbVie, showcases his ability to navigate complex corporate landscapes in the biotech space.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is at the forefront of advancing clinical immunotherapies. Their flagship product, soquelitinib, is an investigational small molecule designed to selectively inhibit ITK, setting the stage for novel treatments in a variety of cancer indications. Corvus aims to revolutionize treatment paradigms with their innovative clinical programs and brings a commitment to fulfilling unmet medical needs in oncology and related diseases.
Frequently Asked Questions
What position has Richard A. van den Broek been appointed to?
Richard A. van den Broek has been appointed to the board of directors at Corvus Pharmaceuticals.
What is ITK inhibition?
ITK inhibition is a promising therapeutic approach aimed at modulating immune responses to treat various cancers and immune diseases.
What is soquelitinib?
Soquelitinib is an investigational drug by Corvus Pharmaceuticals designed to selectively inhibit ITK, currently being developed for cancer treatments.
How does Mr. van den Broek’s experience benefit Corvus?
His extensive background in biotech investment and oversight will provide strategic guidance as Corvus advances its clinical programs.
What are Corvus Pharmaceuticals' goals?
Corvus aims to innovate in the field of immunotherapy and address unmet medical needs in oncology through the development of novel therapies.
